SpHincterotomy for Acute Recurrent Pancreatitis Trial

Date Added
May 15th, 2018
PRO Number
Pro00078002
Researcher
Badih Elmunzer

List of Studies


Keywords
Pancreas
Summary

The purpose of this study is to determine if a procedure called Endoscopic Retrograde CholangioPancreatography (ERCP) with sphincterotomy reduces the risk of pancreatitis or the number of recurrent pancreatitis episodes in patients with pancreas divisum. ERCP with sphincterotomy is a procedure where doctors used a combination of x-rays and an endoscope (a long flexible lighted tube) to find the opening of the duct where fluid drains out of the pancreas. People who have been diagnosed with pancreas divisum, have had at least two episodes of pancreatitis, and are candidates for the ERCP with sphincterotomy procedure may be eligible to participate. Participants will be will be randomly assigned to either have the ERCP with sphincterotomy procedure, or to have a "sham" procedure, meaning that you will be treated as if you are having the ERCP with sphincterotomy procedure but the procedure will not really be performed. Participants will have follow up visits 30 days after the procedure, 6 months after the procedure, and continuing every 6 months until the study ends.

Institution
MUSC
Recruitment Contact
April Williams
(843) 792-3316
williamsa@musc.edu

A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis

Date Added
February 11th, 2020
PRO Number
Pro00092458
Researcher
Kelli Williams

List of Studies


Keywords
Esophagus, Pediatrics
Summary

The main purpose of this study is to see if taking dupilumab is effective in treating Eosinophilic Esophogitis (EoE). The study will determine if dupilumab is an effective treatment compared with placebo in adult and adolescent patients. Dupilumab is administered through a subcutaneous injection (shot). Dupilumab is is an investigational drug, which means that it is not yet approved to treat EoE. Participation in the study will last up to 48 weeks.

Institution
MUSC
Recruitment Contact
Natalie Naylon
843-792-5824
naylon@musc.edu

At-Home vs. In-Clinic Administration of Cabenuva for Treatment of HIV Infection

Date Added
August 17th, 2021
PRO Number
Pro00110879
Researcher
Eric Meissner

List of Studies


Keywords
HIV / AIDS
Summary

Adult patients (18 years and older) who receive treatment for HIV in the MUSC Infectious Diseases Clinic will be offered participation in this study. This study will asses whether receipt of injectable HIV therapy at home with a Home Health provider is as safe and effective as receiving treatment in clinic. Participants receiving injectable HIV therapy prescribed by their primary HIV physician will choose to receive the monthly injection at home or in a clinic setting and will have the option to change where they receive treatment at any time. Questionnaires will be completed at the beginning and end of treatment along with a monthly satisfaction survey. Participation in the study is expected to last approximately 1 year.

Institution
MUSC
Recruitment Contact
Jamila Williams
843-792-1088
keithja@musc.edu



-- OR --